Pancreatic Cancer Research

ResearcherNebraska Medical CenterActive in the last 2 years

Sushil Kumar K

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2155-3443; OpenAlex author ID A5086534465. Sources: OpenAlex.

Their work

Papers
34 (first author 5, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
90
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 8 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 34

  1. Unique N-glycoproteomics and phosphoproteomics of mucins predict clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218653↗
  2. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  3. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  4. Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216185↗
  5. Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Last author DOI 10.1038/s41388-022-02587-1↗
  6. MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1073820↗
  7. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  8. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Last author DOI 10.1016/j.semcancer.2022.03.021↗
  9. Chemokine-mucinome interplay in shaping the heterogeneous tumor microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2022.03.022↗
  10. Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. Co-author DOI 10.1016/j.semcancer.2022.08.009↗
  11. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  12. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance. Co-author DOI 10.1053/j.gastro.2021.09.017↗
  13. Mucin 5AC-Mediated CD44/ITGB1 Clustering Mobilizes Adipose-Derived Mesenchymal Stem Cells to Modulate Pancreatic Cancer Stromal Heterogeneity. Co-author DOI 10.1053/j.gastro.2022.02.032↗
  14. Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies. Co-author DOI 10.7150/thno.64805↗
  15. Polyanhydride nanoparticles stabilize pancreatic cancer antigen MUC4β. Co-author DOI 10.1002/jbm.a.37080↗
  16. Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-021-01800-4↗
  17. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  18. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. First author DOI 10.1016/j.smim.2020.101391↗
  19. Global analysis of human glycosyltransferases reveals novel targets for pancreatic cancer pathogenesis. Co-author DOI 10.1038/s41416-020-0772-3↗
  20. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1096/fj.201902990r↗
  21. CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
  22. Emerging trends in the immunotherapy of pancreatic cancer. First author DOI 10.1016/j.canlet.2017.12.012↗
  23. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Co-author DOI 10.18632/genesandcancer.171↗
  24. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Co-author DOI 10.18632/oncotarget.25036↗
  25. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. First author DOI 10.1080/14728222.2017.1323880↗
  26. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. First author DOI 10.1016/j.biomaterials.2016.05.042↗
  27. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.04.007↗
  28. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Co-author DOI 10.1038/onc.2014.154↗
  29. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Co-author DOI 10.1038/onc.2014.409↗
  30. Mucins in pancreatic cancer and its microenvironment. First author DOI 10.1038/nrgastro.2013.120↗
  31. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Co-author DOI 10.1186/1756-8722-5-68↗
  32. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Co-author DOI 10.1038/bjc.2011.31↗
  33. Monoclonal antibodies recognizing the non-tandem repeat regions of the human mucin MUC4 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0023344↗
  34. Pathobiological implications of MUC16 expression in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0026839↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 33 shared papers, 2011–2026 · strength 3.87
  2. Maneesh Jain · 20 shared papers, 2011–2024 · strength 2.07
  3. Moorthy Palanimuthu Ponnusamy · 12 shared papers, 2011–2024 · strength 1.16
  4. Satyanarayana Rachagani · 13 shared papers, 2011–2024 · strength 1.04
  5. Pranita Atri · 8 shared papers, 2018–2024 · strength 1.01
  6. Rakesh Bhatia · 8 shared papers, 2017–2023 · strength 0.99
  7. Koelina Ganguly · 6 shared papers, 2021–2024 · strength 0.91
  8. Namita Bhyravbhatla · 4 shared papers, 2022–2026 · strength 0.90
  9. Jesse L. Cox · 6 shared papers, 2021–2024 · strength 0.85
  10. Lynette M. Smith · 8 shared papers, 2011–2024 · strength 0.83
  11. Sanchita Rauth · 6 shared papers, 2021–2024 · strength 0.82
  12. Christopher M. Thompson · 6 shared papers, 2018–2023 · strength 0.74
  13. Ashu Shah · 5 shared papers, 2021–2024 · strength 0.69
  14. Andrew C. Cannon · 6 shared papers, 2017–2023 · strength 0.65
  15. Joyce C. Solheim · 5 shared papers, 2018–2022 · strength 0.64
  16. Shailendra Kumar Gautam · 6 shared papers, 2017–2022 · strength 0.64
  17. Zahraa Wajih Alsafwani · 2 shared papers, 2023–2026 · strength 0.60
  18. Xiaoqi Li · 3 shared papers, 2022–2023 · strength 0.51
  19. Rama Krishna Nimmakayala · 4 shared papers, 2020–2023 · strength 0.51
  20. Parthasarathy Seshacharyulu · 4 shared papers, 2012–2024 · strength 0.44
  21. Ramakanth Chirravuri‐Venkata · 3 shared papers, 2022–2023 · strength 0.40
  22. Dipakkumar R. Prajapati · 3 shared papers, 2020–2023 · strength 0.39
  23. Sukhwinder Kaur · 6 shared papers, 2011–2022 · strength 0.38
  24. Palanisamy Nallasamy · 3 shared papers, 2020–2022 · strength 0.33
  25. Balaji Narasimhan · 3 shared papers, 2018–2022 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.